` BLFS (BioLife Solutions Inc) vs S&P 500 Comparison - Alpha Spread

BLFS
vs
S&P 500

Over the past 12 months, BLFS has underperformed S&P 500, delivering a return of -4% compared to the S&P 500's +13% growth.

Stocks Performance
BLFS vs S&P 500

Loading
BLFS
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
BLFS vs S&P 500

Loading
BLFS
S&P 500
Difference
www.alphaspread.com

Performance By Year
BLFS vs S&P 500

Loading
BLFS
S&P 500
Add Stock

Competitors Performance
BioLife Solutions Inc vs Peers

S&P 500
BLFS
ALC
7741
COLO B
ALGN
Add Stock

BioLife Solutions Inc
Glance View

Market Cap
990.4m USD
Industry
Health Care

BioLife Solutions Inc., hailing from Bothell, Washington, tells a story of innovation within the niche yet critical biopreservation industry. Emerging as a vital player for cell and gene therapy developers, BioLife Solutions specializes in creating hypothermic storage and transport media tailored for fragile biologic material. Their cornerstone products, like CryoStor and HypoThermosol, are formulated to prolong the shelf-life and viability of cells, tissues, and organs during storage and transportation. These solutions are designed for ultra-cold environments, ensuring the cellular integrity required by biopharmaceutical companies and research institutions engaged in the leading-edge development of regenerative medicine. The company's business model is centered around both direct sales and strategic partnerships. By deeply embedding its proprietary preservation media into clinical-grade processes, BioLife Solutions establishes itself as an integral component of its clients' supply chains. In doing so, the company generates revenue not just from initial sales of its products, but from ongoing usage as therapies move through development pipelines into mainstream clinical applications. Additionally, their diversification into automated thawing devices and personalized medicine services bolster recurring revenue streams, positioning them strategically in an expanding market driven by technological advancements in cellular therapies. Thus, BioLife Solutions stands firmly at the confluence of innovation and necessity, drawing strength from its strategic foresight and commitment to preserving the future of medicine.

BLFS Intrinsic Value
8.49 USD
Overvaluation 59%
Intrinsic Value
Price
Back to Top